B
BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.
NASDAQ: BBOT (BridgeBio Oncology Therapeutics)
Last update: 7 hours ago3.89
-0.05 (-1.27%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | BridgeBio Oncology Therapeutics | Mixed | Bearish |
AIStockmoo Score
0.5
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Average | 0.50 |
|
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Deerfield Management Company, L.P. | 30 Jun 2026 | 4,885,446 |
| Omega Fund Management, Llc | 30 Jun 2026 | 3,289,661 |
| Ecor1 Capital, Llc | 30 Jun 2026 | 2,823,126 |
| Alphabet Inc. | 30 Jun 2026 | 2,823,126 |
| Enavate Sciences Gp, Llc | 30 Jun 2026 | 2,626,946 |
| Novo Holdings A/S | 30 Jun 2026 | 2,250,000 |
| Laurion Capital Management Lp | 30 Jun 2026 | 2,002,701 |
| Armistice Capital, Llc | 30 Jun 2026 | 1,764,000 |
| Aisling Capital Management Lp | 30 Jun 2026 | 1,018,018 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |